Vrahnas Christina, Pearson Thomas A, Brunt Athena R, Forwood Mark R, Bambery Keith R, Tobin Mark J, Martin T John, Sims Natalie A
St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia; The University of Melbourne, Department of Medicine at St. Vincent's Hospital, Fitzroy, Victoria, Australia.
School of Medical Science, Griffith University, Gold Coast, Queensland, Australia.
Bone. 2016 Dec;93:146-154. doi: 10.1016/j.bone.2016.09.022. Epub 2016 Sep 28.
Intermittent administration of parathyroid hormone (PTH) is used to stimulate bone formation in patients with osteoporosis. A reduction in the degree of matrix mineralisation has been reported during treatment, which may reflect either production of undermineralised matrix or a greater proportion of new matrix within the bone samples assessed. To explore these alternatives, high resolution synchrotron-based Fourier Transform Infrared Microspectroscopy (sFTIRM) coupled with calcein labelling was used in a region of non-remodelling cortical bone to determine bone composition during anabolic PTH treatment compared with region-matched samples from controls. 8week old male C57BL/6 mice were treated with vehicle or 50μg/kg PTH, 5 times/week for 4weeks (n=7-9/group). Histomorphometry confirmed greater trabecular and periosteal bone formation and 3-point bending tests confirmed greater femoral strength in PTH-treated mice. Dual calcein labels were used to match bone regions by time-since-mineralisation (bone age) and composition was measured by sFTIRM in six 15μm regions at increasing depth perpendicular to the most immature bone on the medial periosteal edge; this allowed in situ measurement of progressive changes in bone matrix during its maturation. The sFTIRM method was validated in vehicle-treated bones where the expected progressive increases in mineral:matrix ratio and collagen crosslink type ratio were detected with increasing bone maturity. We also observed a gradual increase in carbonate content that strongly correlated with an increase in longitudinal stretch of the collagen triple helix (amide I:amide II ratio). PTH treatment did not alter the progressive changes in any of these parameters from the periosteal edge through to the more mature bone. These data provide new information about how the bone matrix matures in situ and confirm that bone deposited during PTH treatment undergoes normal collagen maturation and normal mineral accrual.
间歇性给予甲状旁腺激素(PTH)用于刺激骨质疏松症患者的骨形成。据报道,治疗期间基质矿化程度有所降低,这可能反映了矿化不足基质的产生,或者在所评估的骨样本中,新基质占比更高。为探究这些可能性,将基于同步加速器的高分辨率傅里叶变换红外显微光谱法(sFTIRM)与钙黄绿素标记相结合,用于非重塑皮质骨区域,以确定与对照组区域匹配的样本在PTH促合成治疗期间的骨成分。8周龄雄性C57BL/6小鼠接受载体或50μg/kg PTH治疗,每周5次,共4周(每组n = 7 - 9只)。组织形态计量学证实,PTH治疗的小鼠小梁和骨膜骨形成增加,三点弯曲试验证实股骨强度增加。使用双钙黄绿素标记按矿化时间(骨龄)匹配骨区域,并通过sFTIRM在垂直于内侧骨膜边缘最不成熟骨的深度增加的六个15μm区域测量成分;这允许在骨基质成熟过程中对其进行原位测量。sFTIRM方法在接受载体治疗的骨骼中得到验证,在这些骨骼中,随着骨成熟度增加,检测到矿物质:基质比率和胶原交联类型比率呈预期的逐渐增加。我们还观察到碳酸盐含量逐渐增加,这与胶原三螺旋的纵向拉伸增加(酰胺I:酰胺II比率)密切相关。PTH治疗并未改变从骨膜边缘到更成熟骨的任何这些参数的渐进变化。这些数据提供了有关骨基质如何原位成熟的新信息,并证实PTH治疗期间沉积的骨经历正常的胶原成熟和正常的矿物质积累。